Last reviewed · How we verify
Chemotherapy selected by the physician
Physician-selected chemotherapy regimens work by damaging cancer cell DNA or disrupting cell division to inhibit tumor growth.
Physician-selected chemotherapy regimens work by damaging cancer cell DNA or disrupting cell division to inhibit tumor growth. Used for Various solid tumors and hematologic malignancies (specific indication depends on physician selection).
At a glance
| Generic name | Chemotherapy selected by the physician |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This entry represents a flexible, individualized chemotherapy approach where the treating physician selects the specific agent(s) based on tumor type, patient factors, and clinical context. Chemotherapy drugs typically act through DNA alkylation, cross-linking, antimetabolite activity, or mitotic inhibition to kill rapidly dividing cancer cells. The mechanism varies depending on which specific chemotherapy agent is chosen.
Approved indications
- Various solid tumors and hematologic malignancies (specific indication depends on physician selection)
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Alopecia
- Mucositis
- Fatigue
- Diarrhea or constipation
Key clinical trials
- Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
- COronoary Microcirculation Analysis NETwork (NA)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy (PHASE2)
- A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy (PHASE2)
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) (PHASE2)
- Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC (PHASE2)
- MRI-Based Preoperative Accelerated Partial Breast Irradiation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: